Application of prostaglandin E2 receptor targeting drug in treatment of diabetic retinopathy

Abstract

The invention discloses application of a prostaglandin E2 receptor targeting drug in treatment of diabetic retinopathy. The level of PGE2 in the vitreous fluid of a diabetic patient rises abnormally,and PGE2 needs to play a role through an EPR receptor. Therefore, when an EP4R inhibitor (AH23848) is injected into the vitreous cavity for treatment, the EP4R inhibitor inhibits the expression of anEP4R receptor, so that the PGE2 effect is inhibited, the expression of NLPR3 and IL-1 beta mRNA levels in RMECs is reduced, the damage of retinal microvascular endothelial cells in DR is reduced, andthe effect of treating proliferative diabetic retinopathy is achieved. Through detection, analysis and summarization of the inventor, the inventor analyzes and determines the pathogenesis of DR and determines that the development of DR is mediated by various inflammatory factors, fibrosis factors and angiogenesis promoting factors, so that based on the treatment target of the targeted prostaglandin E2 receptor, the drug for effectively treating DR is screened and the use method of the drug is provided.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a drug targeting prostaglandin E2 receptors in the treatment of diabetic retinopathy. Background technique [0002] Diabetic retinopathy (DR) is one of the most common and serious microvascular complications of diabetes, and has become the leading cause of blindness in the world. DR is mainly divided into non-proliferative (Non-Proliferative Diabetic Retinopathy, NPDR) and proliferative (Proliferative Diabetic Retinopathy, PDR) two. NPDR is mainly caused by leakage and occlusion of retinal microvessels, leading to macular edema or local ischemia, and visual impairment; PDR is further developed from NPDR, and hypoxic retinal tissue releases vascular endothelial growth factor (VEGF) ), induce retinal microvascular endothelial cells (retinalmicrovascular endothelial cells, RMECs) to proliferate and form pathological new blood vessels, the above-mentioned vascula...

AI Technical Summary

Problems solved by technology

However, although intraocular injection of anti-VEGF drugs can improve vascular leakage and pathological angiogenesis in DR, the efficacy varies greatly among individuals.

Therefore, as a way of drug treatment, anti-neovascular drug therapy alone is not enough to block or improve other signaling pathways involved in the occurrence and development of retinal vascular lesions and their upstream initiating factors, such as the release of inflammatory factors and not well controlled

In addition, surgical intervention can only stop or slow down the development of late complications of retinal vascular disease, and some surgery-related complications such as cataract, retinal detachment, intraocular infection, etc. may occur

Images